{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:58:38Z","timestamp":1791226718130,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jchf.2024.04.017","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T06:02:37Z","timestamp":1715493757000},"page":"1566-1582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk"],"prefix":"10.1016","volume":"12","author":[{"given":"Andrew P.","family":"Ambrosy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertino","family":"Damasceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Kimmoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Gayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadiza","family":"Saidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-7722","authenticated-orcid":false,"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Celutkiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-9336","authenticated-orcid":false,"given":"Jozine M.","family":"Ter Maaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil\u0117","family":"\u010cerlinskait\u0117-Bajor\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sliwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Novosadova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianela","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9298-7871","authenticated-orcid":false,"given":"Matteo","family":"Pagnesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Arrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.04.017_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction [published correction appears in JACC Heart Fail. 2022;10:295-296]","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10.1016\/j.jchf.2024.04.017_bib2","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/ejhf.1575","article-title":"Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study","volume":"21","author":"Kimmoun","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.jchf.2024.04.017_bib3","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/ejhf.2348","article-title":"Amended STRONG-HF study design","volume":"23","author":"Cotter","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"10367","key":"10.1016\/j.jchf.2024.04.017_bib4","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2024.04.017_bib5","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/ejhf.2920","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: a sub-analysis of the STRONG-HF randomized clinical trial","volume":"25","author":"Arrigo","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.017_bib6","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ejhf.2882","article-title":"Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG-HF trial","volume":"25","author":"\u010cerlinskait\u0117-Bajor\u0117","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"31","key":"10.1016\/j.jchf.2024.04.017_bib7","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/eurheartj\/ehad335","article-title":"NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial","volume":"44","author":"Adamo","year":"2023","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.jchf.2024.04.017_bib8","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","article-title":"Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction","volume":"81","author":"Pagnesi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.04.017_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1745-6215-11-85","article-title":"Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal","volume":"11","author":"Kent","year":"2010","journal-title":"Trials"},{"issue":"19","key":"10.1016\/j.jchf.2024.04.017_bib10","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.04.017_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ejhf.32","article-title":"Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish Heart Failure Registry","volume":"16","author":"Sartipy","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10.1016\/j.jchf.2024.04.017_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009594","article-title":"Meta-Analysis Global Group in Chronic (MAGGIC) heart failure risk score: validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction","volume":"7","author":"Rich","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jchf.2024.04.017_bib13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ehf2.12278","article-title":"Performance of the MAGGIC heart failure risk score and its modification with the addition of discharge natriuretic peptides","volume":"5","author":"Sawano","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.017_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.jchf.2024.04.017_bib15","series-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/j.jchf.2024.04.017_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCOUTCOMES.109.854877","article-title":"A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program","volume":"3","author":"Peterson","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jchf.2024.04.017_bib17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jama.293.5.572","article-title":"Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis","volume":"293","author":"Fonarow","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2024.04.017_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacc.2008.04.028","article-title":"Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"52","author":"Abraham","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.04.017_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ahj.2015.04.006","article-title":"Predictors of clinical outcomes in acute decompensated heart failure: acute study of clinical effectiveness of nesiritide in decompensated heart failure outcome models","volume":"170","author":"Khazanie","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2024.04.017_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/eurjhf\/hfs029","article-title":"The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction","volume":"14","author":"O'Connor","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.017_bib21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jchf.2024.04.017_bib22","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jchf.2024.04.017_bib23","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.294.10.1240","article-title":"Risk-treatment mismatch in the pharmacotherapy of heart failure","volume":"294","author":"Lee","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2024.04.017_bib24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10741-021-10077-x","article-title":"Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction","volume":"27","author":"Greene","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2024.04.017_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","article-title":"Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: a secondary analysis of a randomized clinical trial","volume":"5","author":"Fiuzat","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2024.04.017_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jchf.2022.08.023","article-title":"Treatment differences in medical therapy for heart failure with reduced ejection fraction between sociodemographic groups","volume":"11","author":"Witting","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.jchf.2024.04.017_bib27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ejhf.3066","article-title":"Hypotension in heart failure is less harmful if associated with high or increasing doses of heart failure medication: insights from the Swedish Heart Failure Registry","volume":"26","author":"Girerd","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.jchf.2024.04.017_bib28","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/ejhf.3049","article-title":"Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from Swedish Heart Failure Registry","volume":"25","author":"Guidetti","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.017_bib29","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ejhf.2508","article-title":"Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure)","volume":"24","author":"McNaughton","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.017_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ahj.2016.12.017","article-title":"Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial","volume":"186","author":"Ambrosy","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2024.04.017_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002458","article-title":"Changes in dyspnea status during hospitalization and postdischarge health-related quality of life in patients hospitalized for heart failure: findings from the EVEREST trial","volume":"9","author":"Ambrosy","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.017_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ejhf.420","article-title":"The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF","volume":"18","author":"Ambrosy","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10.1016\/j.jchf.2024.04.017_bib33","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.017_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009837","article-title":"Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: pooled patient-level analysis from DEFINE-HF and PRESERVED-HF trials","volume":"16","author":"Nassif","year":"2023","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10.1016\/j.jchf.2024.04.017_bib35","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1016\/j.jchf.2026.103358","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924003378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924003378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:38:33Z","timestamp":1787171913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924003378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2213177924003378"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.04.017","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}